Key result
Immune complexes regulate atherosclerosis, with pro-atherogenic IgG and protective IgM acting via Fc and complement pathways.
Answers are grounded in this paper and cite their sources.
Atherosclerosis is now recognized as a chronic inflammatory disease and is characterized by features of inflammation at all stages of its development. It also appears to display elements of autoimmunity, and several autoantibodies including those directed against oxidized low-density lipoprotein (ox-LDL) and heat shock proteins (Hsps) have been identified in atherosclerosis. Immune complexes (ICs) may form between these antigens and autoantibodies and via Fc receptor signaling and complement activation may modulate the inflammation in atherosclerosis. Antibody isotype may direct the role that ICs play in atherogenesis, immunoglobulin G (IgG) being potentially pro-atherogenic and immunoglobulin M (IgM) playing a protective role. Therapeutic options targeting complement activation and those which are potentially Fc-receptor mediated have been investigated in animal models, though targeting Fc receptor signaling is an area that needs further investigation.
No takes yet. Share an insight, caveat, or question.
Burut et al. (2010) conducted a review in Atherosclerosis. Immune complexes (autoantibodies against ox-LDL and heat shock proteins) was evaluated. Immune complexes modulate inflammation in atherosclerosis via Fc receptor signaling and complement activation, with IgG being potentially pro-atherogenic and IgM protective.
Synapse has enriched 10 related papers. Consider them for comparative context: